Shandong Weigao Group Medical Polymer Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Rinan Cong
Chief Executive Officer (CEO)
CN¥4.0m
Compensación total
| Porcentaje del salario del CEO | 42.1% |
| Permanencia del CEO | no data |
| Participación del CEO | 0.05% |
| Permanencia media de la dirección | 2.5yrs |
| Promedio de permanencia en la Junta Directiva | 2.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?
Nov 26
Be Wary Of Shandong Weigao Group Medical Polymer (HKG:1066) And Its Returns On Capital
Nov 04Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report
Sep 24Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target
Aug 30Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 27% Share Price Plunge Could Signal Some Risk
Jun 25Here's What To Make Of Shandong Weigao Group Medical Polymer's (HKG:1066) Decelerating Rates Of Return
Jun 23Shandong Weigao Group Medical Polymer's (HKG:1066) Shareholders Will Receive A Bigger Dividend Than Last Year
May 31We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope
May 22Earnings Not Telling The Story For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Apr 23Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results
Mar 28Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon
Jan 09Returns On Capital Are Showing Encouraging Signs At Shandong Weigao Group Medical Polymer (HKG:1066)
Dec 22Are Investors Undervaluing Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) By 44%?
Nov 10Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?
Oct 05Return Trends At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Appealing
Aug 01Is Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Trading At A 28% Discount?
Jul 19Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth
Jun 22Is Shandong Weigao Group Medical Polymer (HKG:1066) Using Too Much Debt?
Jun 09The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing
Apr 27Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth
Mar 17A Look At The Intrinsic Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Feb 27Returns On Capital At Shandong Weigao Group Medical Polymer (HKG:1066) Have Hit The Brakes
Jan 18Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?
Dec 12Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 21% Below Their Intrinsic Value Estimate
Nov 29Here's Why We Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today
Nov 14Shandong Weigao Group Medical Polymer (HKG:1066) Is Paying Out A Larger Dividend Than Last Year
Oct 03The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing
Sep 21Shandong Weigao Group Medical Polymer (HKG:1066) Could Easily Take On More Debt
Sep 05Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Intrinsic Value Is Potentially 27% Above Its Share Price
Aug 23Here's Why Shandong Weigao Group Medical Polymer (HKG:1066) Has Caught The Eye Of Investors
Aug 08There's Been No Shortage Of Growth Recently For Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital
Jun 22Shandong Weigao Group Medical Polymer (HKG:1066) Will Pay A Smaller Dividend Than Last Year
Jun 08An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 27% Undervalued
May 16Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?
May 03Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital Are Heading Higher
Mar 17Is There An Opportunity With Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 42% Undervaluation?
Jan 28Does Shandong Weigao Group Medical Polymer (HKG:1066) Deserve A Spot On Your Watchlist?
Jan 13Returns Are Gaining Momentum At Shandong Weigao Group Medical Polymer (HKG:1066)
Dec 17Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly
Dec 05An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 32% Undervalued
Oct 18Do Shandong Weigao Group Medical Polymer's (HKG:1066) Earnings Warrant Your Attention?
Oct 06Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥2b |
| Mar 31 2024 | n/a | n/a | CN¥2b |
| Dec 31 2023 | CN¥4m | CN¥2m | CN¥2b |
| Sep 30 2023 | n/a | n/a | CN¥2b |
| Jun 30 2023 | n/a | n/a | CN¥2b |
| Mar 31 2023 | n/a | n/a | CN¥3b |
| Dec 31 2022 | CN¥5m | CN¥950k | CN¥3b |
| Sep 30 2022 | n/a | n/a | CN¥3b |
| Jun 30 2022 | n/a | n/a | CN¥3b |
| Mar 31 2022 | n/a | n/a | CN¥2b |
| Dec 31 2021 | CN¥3m | CN¥903k | CN¥2b |
Compensación vs. Mercado: La compensación total ($USD546.64K) de Rinan está en línea con el promedio de empresas de tamaño similar en el mercado Hong Kong ($USD493.39K).
Compensación vs. Ingresos: La compensación de Rinan ha sido consistente con los resultados de la empresa en el último año.
CEO
Rinan Cong (43 yo)
no data
Permanencia
CN¥3,990,000
Compensación
Mr. Rinan Cong served as Chief Executive Officer at Shandong Weigao Group Medical Polymer Company Limited since March 30, 2021 until 2024 and served as Executive Director since May 24, 2021 until 2024 and...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman of the Board & Compliance Officer | 6yrs | CN¥8.27m | 0.14% HK$ 30.0m | |
| Chief Executive Officer | no data | CN¥3.99m | 0.048% HK$ 10.2m | |
| Executive Director | 2.5yrs | CN¥1.32m | sin datos | |
| Chief Financial Officer | 7.8yrs | sin datos | sin datos | |
| Non-Executive Director | less than a year | sin datos | sin datos | |
| Executive Director | less than a year | sin datos | 0.011% HK$ 2.3m | |
| Company Secretary | 18.6yrs | sin datos | sin datos |
2.5yrs
Permanencia media
49yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de 1066 se considera experimentado (2.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman of the Board & Compliance Officer | 6yrs | CN¥8.27m | 0.14% HK$ 30.0m | |
| Executive Director | 2.5yrs | CN¥1.32m | sin datos | |
| Non-Executive Director | less than a year | sin datos | sin datos | |
| Executive Director | less than a year | sin datos | 0.011% HK$ 2.3m | |
| Non-Executive Director | 3.8yrs | sin datos | sin datos | |
| Independent Non-Executive Director | 2.3yrs | CN¥150.00k | sin datos | |
| Independent Non-Executive Director | 2.5yrs | CN¥207.00k | sin datos | |
| Vice Chairman | 3.8yrs | sin datos | sin datos | |
| Chairman of the Supervisors | 4.4yrs | sin datos | sin datos | |
| Employee Representative Supervisor | 2.7yrs | sin datos | sin datos | |
| Independent Non-Executive Director | 2yrs | CN¥150.00k | sin datos | |
| Independent Non-Executive Director | less than a year | sin datos | sin datos |
2.5yrs
Permanencia media
49yo
Promedio de edad
Junta con experiencia: La junta directiva de 1066 no se considera experimentada (2.5 años de permanencia promedio), lo que sugiere una nueva junta directiva.
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2024/12/30 19:11 |
| Precio de las acciones al final del día | 2024/12/30 00:00 |
| Beneficios | 2024/06/30 |
| Ingresos anuales | 2023/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas
Shandong Weigao Group Medical Polymer Company Limited está cubierta por 35 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jason Mann | Barclays |
| Derrick Sun | BNP Paribas Securities (Asia) |
| Feng Qiang Sun | BOCOM International Securities Limited |